Boulder-based Clovis Oncology, a developer of cancer treatments, had its IPO Wednesday, raising $130M for the company in its first day as a public company. The firm is trading on the NASDAQ Global Market as CLVS. The firm debuted at $13.00 per share, and closed slightly down on its first day at $12.56. Clovis was venture backed by Domain Associates, New Enterprise Associates, Versant Ventures, Aberdare Ventures, Abingworth Bioventures, and Pfizer.